Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.41 |
| ▸ | CA2 | P00918 | 11/20 | 0.41 |
| ▸ | CA9 | Q16790 | 11/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 11/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13972868 | 1.00 | CA1 (0.41) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4418374 | 0.84 | FPR2 (0.42) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4422235 | 0.83 | KDM4E (0.48) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4414666 | 0.83 | ALDH1A1 (0.40) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL13972641 | 0.82 | GAA (0.40) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4416959 | 0.82 | GAA (0.40) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4414625 | 0.82 | CA1 (0.45) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4412965 | 0.81 | HCRTR1 (0.44) | CA1CA2CA9CA14FKBP1A | |
| SCHEMBL4414908 | 0.81 | PKM (0.48) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4422262 | 0.80 | NPSR1 (0.40) | CA1CA2CA9CA14PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| EP-1663983-A1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
| WO-2004113302-A1 | N-SUBSTITUTED 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | CA1 2370/4885CA2 335/4885CA9 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.